Rohit Singhal1, Lisa Aimee Hechanova2. 1. Texas Tech University Health Science Center El Paso, 4800 Alberta Avenue, El Paso, TX, 79905, USA. 2. Texas Tech University Health Science Center El Paso, 4800 Alberta Avenue, El Paso, TX, 79905, USA. Aimee.Hechanova@ttuhsc.edu.
Abstract
PURPOSE OF REVIEW: Over the past few decades, multiple glucose lowering therapies have been developed, but until now, no single drug has proven to both decrease cardiovascular mortality and improve renal outcomes. The purpose of this review is to outline the key findings of the recent major outcome clinical trials on SGLT2 inhibitors, review the indications for their use, and improve adoption of these medications in patients with type 2 diabetes mellitus (T2DM). RECENT FINDINGS: Recent studies have shown a benefit for SGLT2 inhibitors in patients with heart failure (HF) and kidney disease both in the presence and absence of T2DM. Additional benefits also include improvements in fluid status, blood pressure, serum uric acid levels, and weight loss. Available data suggests that SGLT2 inhibitors should be used in all eligible patients with HFrEF and/or CKD with albuminuria to decrease progression of CKD, hospitalizations for heart failure, major atherosclerotic cardiovascular events, and cardiovascular death, with and without T2DM.
PURPOSE OF REVIEW: Over the past few decades, multiple glucose lowering therapies have been developed, but until now, no single drug has proven to both decrease cardiovascular mortality and improve renal outcomes. The purpose of this review is to outline the key findings of the recent major outcome clinical trials on SGLT2 inhibitors, review the indications for their use, and improve adoption of these medications in patients with type 2 diabetes mellitus (T2DM). RECENT FINDINGS: Recent studies have shown a benefit for SGLT2 inhibitors in patients with heart failure (HF) and kidney disease both in the presence and absence of T2DM. Additional benefits also include improvements in fluid status, blood pressure, serum uric acid levels, and weight loss. Available data suggests that SGLT2 inhibitors should be used in all eligible patients with HFrEF and/or CKD with albuminuria to decrease progression of CKD, hospitalizations for heart failure, major atherosclerotic cardiovascular events, and cardiovascular death, with and without T2DM.
Authors: Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll Journal: N Engl J Med Date: 2016-09-15 Impact factor: 91.245
Authors: Rury R Holman; M Angelyn Bethel; Robert J Mentz; Vivian P Thompson; Yuliya Lokhnygina; John B Buse; Juliana C Chan; Jasmine Choi; Stephanie M Gustavson; Nayyar Iqbal; Aldo P Maggioni; Steven P Marso; Peter Öhman; Neha J Pagidipati; Neil Poulter; Ambady Ramachandran; Bernard Zinman; Adrian F Hernandez Journal: N Engl J Med Date: 2017-09-14 Impact factor: 91.245
Authors: Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245
Authors: William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang Journal: N Engl J Med Date: 2008-12-17 Impact factor: 91.245
Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245